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ORIGINAL INVESTIGATION
LEADER 5: prevalence 
and cardiometabolic impact of obesity 
in cardiovascular high-risk patients with type 2 
diabetes mellitus: baseline global data from the 
LEADER trial
L. Masmiquel1*, L. A. Leiter2, J. Vidal3, S. Bain4, J. Petrie5, E. Franek6, I. Raz7, A. Comlekci8, S. Jacob9, L. van Gaal10, 
F. M. M. Baeres11, S. P. Marso12, M. Eriksson13 and on behalf of the LEADER investigators
Abstract 
Background: Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus 
(T2DM) and high cardiovascular (CV) risk. We used the baseline data of liraglutide effect and action in diabetes: evalu-
ation of CV outcome results—A long term Evaluation (LEADER) (a clinical trial to assess the CV safety of liraglutide) to 
investigate: (i) prevalence of overweight and obesity; (ii) relationship of the major cardiometabolic risk factors with 
anthropometric measures of adiposity [body mass index (BMI) and waist circumference (WC)]; and (iii) cardiometa-
bolic treatment intensity in relation to BMI and WC.
Methods: LEADER enrolled two distinct populations of high-risk patients with T2DM in 32 countries: (1) 
aged ≥50 years with prior CV disease; (2) aged ≥60 years with one or more CV risk factors. Associations of metabolic 
variables, demographic variables and treatment intensity with anthropometric measurements (BMI and WC) were 
explored using regression models (ClinicalTrials.gov identifier: NCT01179048).
Results: Mean BMI was 32.5 ± 6.3 kg/m2 and only 9.1 % had BMI <25 kg/m2. The prevalence of healthy WC was 
also extremely low (6.4 % according to International Joint Interim Statement for the Harmonization of the Metabolic 
Syndrome criteria). Obesity was associated with being younger, female, previous smoker, Caucasian, American, with 
shorter diabetes duration, uncontrolled blood pressure (BP), antihypertensive agents, insulin plus oral antihypergly-
caemic treatment, higher levels of triglycerides and lower levels of high-density lipoprotein cholesterol.
Conclusions: Overweight and obesity are prevalent in high CV risk patients with T2DM. BMI and WC are related to 
the major cardiometabolic risk factors. Furthermore, treatment intensity, such as insulin, statins or oral antihyperten-
sive drugs, is higher in those who are overweight or obese; while BP and lipid control in these patients are remarkably 
suboptimal. LEADER confers a unique opportunity to explore the longitudinal effect of weight on CV risk factors and 
hard endpoints.
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Background
The association between different anthropometric meas-
ures of adiposity and cardiovascular (CV) risk in patients 
with established diabetes and high CV risk has not been 
well studied [1, 2]. Several longitudinal cohort studies 
have shown that patients with coronary artery disease 
and type 2 diabetes mellitus (T2DM) have lower mor-
tality with a higher body mass index (BMI), suggest-
ing that an “obesity paradox” exists [3]. Although lower 
muscle mass in patients with T2DM could be a plausible 
biological explanation for this [4], several confounding 
factors are likely to play a role in this apparent paradox. 
For example, BMI alone is recognised to be an imperfect 
measurement of the type of adiposity. Furthermore, some 
imbalance could be evident in other key parameters, 
including age, lipid levels, degree of metabolic control, 
CV risk factors and treatment intensity [5, 6]. There-
fore, additional data on the associations of these param-
eters are needed, especially in high CV risk patients with 
T2DM.
The LEADER (liraglutide effect and action in diabe-
tes: evaluation of CV outcome results) trial is designed 
to assess formally the CV safety of liraglutide in patients 
with T2DM aged  ≥50  years with history of, or at high 
risk for CV events [7]. We used the cross-sectional base-
line data from LEADER to investigate (i) the prevalence 
of overweight and obesity; (ii) the interplay among the 
major cardiometabolic risk factors and two anthropo-
metric measures of adiposity [BMI and waist circumfer-
ence (WC)]; and (iii) the treatment of cardiometabolic 
risk factors in relation to BMI and WC categories. Fur-
thermore, because race and ethnicity significantly affect 
the associations between anthropometric indices and CV 
risk factors [8–10], we also investigated the influence of 
these characteristics.
Methods
LEADER is a phase 3B, multicentre, international, ran-
domised, double-blind, placebo-controlled clinical trial 
with long-term follow-up designed to assess the CV 
safety of liraglutide up to 1.8  mg daily, a glucagon-like 
peptide-1 receptor agonist (GLP-1RA) approved for 
treatment of patients with T2DM. A detailed descrip-
tion of the study design and baseline characteristics of 
the study population has previously been published [7]. 
Briefly, the trial enrolled a CV high-risk population of 
patients with T2DM at 410 sites in 32 countries who fit 
into one of the following categories: i) patients >50 years 
of age and concomitant CV disease (CVD), cerebrovas-
cular disease, peripheral vascular disease, chronic renal 
failure, or chronic heart failure; ii) patients >60 years of 
age and one or more of the following CV risk factors: 
microalbuminuria or proteinuria, hypertension and 
left ventricular hypertrophy by electrocardiogram or 
imaging, left ventricular dysfunction by imaging, or 
ankle–brachial index of <0.9.
Physical exploration and anthropometric measure-
ments were carried out according to the protocol by 
the investigators with the subject barefoot and wearing 
light clothes. BMI was the ratio of weight (kg) divided by 
squared height (m2). WC was measured from the front 
at the narrowest point between the rib cage and the iliac 
crest when the subject was breathing out gently.
Smoking habits, comorbidities and race/ethnicity were 
documented at study entry. Ethnicity was obtained sepa-
rately from race. The ethnicity was classified as hispanic/
latino or not hispanic/latino; the race was classified as 
Caucasian, Black, Asian, or Other.
All subjects gave written informed consent and the trial 
was approved by the relevant local ethical committees 
and was conducted in conformity with the declaration of 
Helsinki.
Statistical analysis
Data are presented as mean (standard deviation), 
median (interquartile range) or number (%). To examine 
the categorical relationship between BMI and the clini-
cal, epidemiological and biochemical variables, patients 
were divided into the following categories based on 
their BMI (kg/m2):  <25.0 (healthy weight), 25.0 to  <30 
(overweight), 30.0 to <35.0 (obesity grade I), 35.0 to <40 
(obesity grade II),  ≥40.0 (obesity grade III) [11]. For 
the same purpose, WC was dichotomised as healthy/
unhealthy for both the National Cholesterol Education 
Program [adult treatment panel III criteria (ATPIII)] 
[12] (≥88  cm for females and ≥102  cm for males) and 
the International Joint Interim Statement for the Harmo-
nization of the Metabolic Syndrome criteria (IISHMS) 
[13] (Caucasians, Blacks and Others:  ≥94  cm males 
and  ≥80  cm females; Hispanics and Asians:  ≥90  cm 
males and ≥80 cm females) [14].
For statistical purposes, the percentage of patients with 
glycated haemoglobin (HbA1c) ≤8 % (<63.9 mmol/mol) 
was calculated as it is considered to be an appropriate 
target in populations with advanced micro- or macrovas-
cular complications, and extensive comorbid conditions, 
and in those with long-standing diabetes in whom the 
general target of an HbA1c <7.0 % (<53.0 mmol/mol) is 
difficult to attain [15, 16]. Blood pressure (BP) measure-
ments of  <140/80  mmHg, low-density lipoprotein cho-
lesterol (LDL-C)  <2.6  mmol/l (100  mg/dl) (<1.8  mmol/l 
[70  mg/dl] in patients with previous CV events), high-
density lipoprotein cholesterol (HDL-C)  >1.3  mmol/l 
(50 mg/dl) in women and >1.0 mmol/l (40 mg/dl) in men 
and triglycerides  <1.7  mmol/l (150  mg/dl) were consid-
ered to be at target, according to the American Diabetes 
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Association 2014 guidelines (the guidelines available 
when this analysis was conducted) [15].
Associations between BMI or WC with covariates 
and factors were screened initially using Spearman cor-
relation and Chi square or Fisher’s exact test, respec-
tively. Linear regression models were used to describe 
the associations of treatment intensity/metabolic vari-
ables with anthropometric measurements. Likewise, 
logistic regression models were developed to assess the 
association between dichotomised “off-target” anthro-
pometric variables and explanatory factors. Variable 
selection was decided before model fitting; in particu-
lar, BMI was excluded from the analysis of WC and 
vice versa (an overview of variables used in the logistic 
regression model is provided in the data table). Covari-
ates were selected by consideration of potential impact 
on anthropometric measurements, based on review of 
the literature and availability in the LEADER database. 
Main effects of all covariates/factors were retained in the 
model, as the sample size of the LEADER study implied 
no need for further variable selection.
This study is based on the data from all 9340 partici-
pants in the LEADER trial, but numbers may vary due to 
missing data for a small number of participants. Com-
plete data are available for approximately 99 % of partici-
pants. Individuals with missing data were not included in 
the statistical analyses.
A two-sided p value of <0.01 was considered statistically 
significant. Statistical analyses were performed using SAS 
9.3 software (SAS Institute, Cary, NC, USA). Analyses 
were conducted on the data available at baseline.
Results
Demographic and clinical characteristics
Baseline characteristics of all randomised patients 
stratified by prior CVD, BMI and WC are detailed in 
Tables 1–3.
Stratified by CVD
Mean BMI was comparable between patients with 
prior CVD and those without (32.5 vs. 32.4  kg/m2, 
respectively). Comparing patients with prior CVD with 
those without, the prevalence of overweight (28.3 vs. 
29.7  %, respectively), obesity grade I (32.3 vs. 30.6  %, 
respectively), obesity grade II (18.5 vs. 17.7  %, respec-
tively), and obesity grade III (11.6 vs. 12.0 %, respectively) 
was similar (Table 1). Likewise, comparing patients with 
prior CVD with those without mean WC (110.1 and 
109.4  cm, respectively) and the overall prevalence of 
abdominal obesity according to ATPIII (78.1 and 80.0 %, 
Table 1 Demographic and clinical characteristics stratified 
by CVD
Values are expressed as mean ± SD or frequency (percent of row). ATPIII 
Adult treatment panel III criteria; CVD cardiovascular disease; eGFR estimated 
glomerular filtration rate; HbA1c glycated haemoglobin; HDL-C high-density 
lipoprotein cholesterol; IISHMS International Joint Interim Statement for 
the Harmonization of the Metabolic Syndrome criteria; LDL-C low-density 
lipoprotein cholesterol; SD standard deviation; WC waist circumference
All No prior CVD 
group
Prior CVD 
group
(n = 9340) (n = 1748) (n = 7592)
Age (years) 64.3 ± 7.2 65.8 ± 5.2 63.9 ± 7.6
Gender
 Female 3337 (35.7 %) 793 (45.4 %) 2544 (33.5 %)
 Male 6003 (64.3 %) 955 (54.6 %) 5048 (66.5 %)
Age group
 50–59 years 2321 (24.9 %) 26 (1.5 %) 2295 (30.2 %)
 60–69 years 4839 (51.8 %) 1337 (76.5 %) 3502 (46.1 %)
 70–79 years 1977 (21.2 %) 359 (20.5 %) 1618 (21.3 %)
 80–89 years 199 (2.1 %) 26 (1.5 %) 173 (2.3 %)
 90–99 years 4 (0.0 %) 0 (0.0 %) 4 (0.1 %)
BMI (kg/m2)
 <25.0 865 (9.3 %) 172 (9.8 %) 693 (9.1 %)
 25 to <30 2671 (28.6 %) 520 (29.7 %) 2151 (28.3 %)
 30 to <35 2987 (32.0 %) 535 (30.6 %) 2452 (32.3 %)
 35 to <40 1715 (18.4 %) 310 (17.7 %) 1405 (18.5 %)
 ≥40.0 1092 (11.7 %) 210 (12.0 %) 882 (11.6 %)
WC ATIII target
 Yes 1933 (20.7 %) 338 (19.3 %) 1595 (21.0 %)
 No 7330 (78.5 %) 1398 (80.0 %) 5932 (78.1 %)
 Missing values 77 (0.8 %) 12 (0.7 %) 65 (0.9 %)
WC-IISHMS target
 Yes 585 (6.3 %) 100 (5.7 %) 485 (6.4 %)
 No 8678 (92.9 %) 1636 (93.6 %) 7042 (92.8 %)
 Missing values 77 (0.8) 12 (0.7) 65 (0.9 %)
HbA1c (%) 8.7 (1.6) 8.8 (1.5) 8.7 (1.6)
HbA1c (mmol/mol) 71.6 (17.5) 72.7 (16.4) 71.6 (17.5)
Blood lipids
 LDL-C (mmol/L) 2.3 (0.9) 2.5 (0.9) 2.3 (0.9)
 HDL-C (mmol/L) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3)
 Triglycerides (mmol/L) 2.1 (1.6) 2.0 (1.5) 2.1 (1.6)
No OAD use at baseline 4409 (47.2 %) 744 (42.6 %) 3665 (48.3 %)
Pre-treatment
 None/diet 504 (5.4) 99 (5.7) 405 (5.3)
 Insulines only 665 (7.1) 69 (3.9) 596 (7.9)
 OADs only 4931 (52.8) 1004 (57.4) 3927 (51.7)
 Ins + OADs 3240 (34.7) 576 (33.0) 2644 (35.1)
Use of antihypertensive medication
 Yes 8550 (91.5 %) 1473 (84.3 %) 7077 (93.2 %)
 No 790 (8.5 %) 275 (15.7 %) 515 (6.8 %)
Page 4 of 15Masmiquel et al. Cardiovasc Diabetol  (2016) 15:29 
Table 2 Demographic and clinical characteristics stratified by BMI
Values are expressed as mean ± SD or frequency (percent of row). BMI body mass index; CVD cardiovascular disease; eGFR estimated glomerular filtration rate;  
HbA1c glycated haemoglobin; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; SD standard deviation
All <25 kg/m2 25 to <30 kg/m2 30 to <35 kg/m2 35 to <40 kg/m2 ≥40.0 kg/m2
(n = 9330) (n = 865) (n = 2671) (n = 2987) (n = 1715) (n = 1092)
Age (years) 64.3 ± 7.2 64.7 ± 7.7 65.4 ± 7.4 64.4 ± 7.2 63.4 ± 6.8 62.5 ± 6.6
Gender
 Female 3331 262 (7.9 %) 817 (24.5 %) 995 (29.9 %) 706 (21.2 %) 551 (16.5 %)
 Male 5999 603 (10.1 %) 1854 (30.9 %) 1992 (33.2 %) 1009 (16.8 %) 541 (9.0 %)
Age group
 50–59 years 2317 201 (8.7 %) 566 (24.4 %) 729 (31.5 %) 476 (20.5 %) 345 (14.9 %)
 60–69 years 4834 435 (9.0 %) 1327 (27.5 %) 1548 (32.0 %) 922 (19.1 %) 602 (12.5 %)
 70–79 years 1976 201 (10.2 %) 697 (35.3 %) 646 (32.7 %) 298 (15.1 %) 135 (6.8 %)
 80–89 years 199 26 (13.1 %) 80 (40.2 %) 64 (32.2 %) 19 (9.5 %) 10 (5.0 %)
 90–99 years 4 3 (75.0 %) 1 (25.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Region
 Europe 3517 206 (5.9 %) 1019 (29.0 %) 1240 (35.3 %) 667 (19.0 %) 385 (10.9 %)
 Other areas 2616 276 (10.6 %) 807 (30.8 %) 830 (31.7 %) 457 (17.5 %) 246 (9.4 %)
 United States 2487 120 (4.8 %) 529 (21.3 %) 811 (32.6 %) 569 (22.9 %) 458 (18.4 %)
 Asia 710 263 (37.0 %) 316 (44.5 %) 106 (14.9 %) 22 (3.1 %) 3 (0.4 %)
Race
 Asian 920 326 (35.4 %) 395 (42.9 %) 159 (17.3 %) 33 (3.6 %) 7 (0.8 %)
 Black 773 53 (6.9 %) 225 (29.1 %) 227 (29.4 %) 155 (20.1 %) 113 (14.6 %)
 Other 406 57 (14.0 %) 150 (36.9 %) 118 (29.1 %) 50 (12.3 %) 31 (7.6 %)
 Caucasian 7231 429 (5.9 %) 1901 (26.3 %) 2483 (34.3 %) 1477 (20.4 %) 941 (13.0 %)
Ethnicity
 Hispanic or latino 1135 131 (11.5 %) 393 (34.6 %) 357 (31.5 %) 166 (14.6 %) 88 (7.8 %)
 Not hispanic or latino 8195 734 (9.0 %) 2278 (27.8 %) 2630 (32.1 %) 1549 (18.9 %) 1004 (12.3 %)
eGFR category (mL/min/1.73 m2)
 Normal (≥90) 3445 367 (10.7 %) 983 (28.5 %) 1050 (30.5 %) 670 (19.4 %) 375 (10.9 %)
 Mild (60–90) 3854 304 (7.9 %) 1119 (29.0 %) 1299 (33.7 %) 694 (18.0 %) 438 (11.4 %)
 Moderate (30–60) 1852 171 (9.2 %) 510 (27.5 %) 600 (32.4 %) 322 (17.4 %) 249 (13.4 %)
 Severe (<30) 177 23 (13.0 %) 58 (32.8 %) 37 (20.9 %) 29 (16.4 %) 30 (16.9 %)
Smoker
 Current smoker 1128 122 (10.8 %) 351 (31.1 %) 359 (31.8 %) 174 (15.4 %) 122 (10.8 %)
 Never smoked 3867 422 (10.9 %) 1108 (28.7 %) 1172 (30.3 %) 718 (18.6 %) 447 (11.6 %)
 Previous smoker 4335 321 (7.4 %) 1212 (28.0 %) 1456 (33.6 %) 826 (19.1 %) 523 (12.1 %)
CVD stratum
 No Prior CVD group 1747 172 (9.8 %) 520 (29.8 %) 535 (30.6 %) 310 (17.7 %) 210 (12.0 %)
 Prior CVD group 7583 693 (9.1 %) 2151 (28.4 %) 2452 (32.3 %) 1405 (18.5 %) 882 (11.6 %)
Diabetes duration (years) 12.7 ± 9.5 14.1 ± 8.8 13.5 ± 8.2 12.4 ± 7.8 12.0 ± 7.7 12.1 ± 7.7
HbA1c (%) 8.7 ± 1.5 8.9 ± 1.8 8.6 ± 1.5 8.6 ± 1.5 8.7 ± 1.5 8.7 ± 1.5
HbA1c (mmol/mol) (71.6 ± 16.4) (73.8 ± 19.7) (70.5 ± 16.4) (70.5 ± 16.4) (71.6 ± 16.4) (71.6 ± 16.4)
Blood lipids
 LDL-C (mmol/L) 2.3 ± 0.9 2.3 ± 0.5 2.3 ± 0.9 2.3 ± 0.9 2.3 ± 0.9 2.3 ± 0.9
 HDL-C (mmol/L) 1.2 ± 0.3 1.2 ± 0.4 1.2 ± 0.3 1.1 ± 0.3 1.2 ± 0.3 1.2 ± 0.3
 Triglycerides (mmol/L) 2.1 ± 1.6 1.6 ± 1.1 1.9 ± 1.5 2.2 ± 1.8 2.2 ± 1.4 2.2 ± 1.7
Blood pressure
 Systolic blood pressure (mmHg) 137.7 ± 18.6 134.5 ± 19.2 137.9 ± 18.5 138.3 ± 18.5 138.1 ± 18.2 137.5 ± 19.3
 Diastolic blood pressure (mmHg) 77.9 ± 10.5 76.4 ± 9.9 77.1 ± 10.2 78.3 ± 10.4 78.9 ± 10.4 78.3 ± 11.5
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Table 3 Demographic and clinical characteristics stratified by WC according ATPIII and IISHMS
Values are expressed as mean ± SD or frequency (percent of row). ATPIII Adult Treatment Panel III criteria; CVD cardiovascular disease; eGFR estimated glomerular 
filtration rate; HbA1c glycated haemoglobin; HDL-C high-density lipoprotein cholesterol; IISHMS International Joint Interim Statement for the Harmonization of the 
Metabolic Syndrome criteria; LDL-C low-density lipoprotein cholesterol; SD standard deviation; WC waist circumference
All WC-ATPIII WC-IISHMS
Off target On target Off target On target
(n = 9263) (n = 7330) (n = 1933) (n = 8678) (n = 585)
Age (years) 64.3 ± 7.2 64.3 ± 7.2 64.3 ± 7.4 64.3 ± 7.2 64.2 ± 7.4
Gender
 Female 3305 3050 (92.3 %) 255 (7.7 %) 3232 (97.8 %) 73 (2.2 %)
 Male 5958 4280 (71.8 %) 1678 (28.2 %) 5446 (91.4 %) 512 (8.6 %)
Age group
 50–59 years 2305 1822 (79.0 %) 483 (21.0 %) 2165 (93.9 %) 140 (6.1 %)
 60–69 years 4806 3835 (79.8 %) 971 (20.2 %) 4501 (93.7 %) 305 (6.3 %)
 70–79 years 1954 1518 (77.7 %) 436 (22.3 %) 1829 (93.6 %) 125 (6.4 %)
 80–89 years 194 153 (78.9 %) 41 (21.1 %) 180 (92.8 %) 14 (7.2 %)
 90–99 years 4 2 (50.0 %) 2 (50.0 %) 3 (75.0 %) 1 (25.0 %)
Region
 Europe 3489 2873 (82.3 %) 616 (17.7 %) 3322 (95.2 %) 167 (4.8 %)
 Other areas 2600 2053 (79.0 %) 547 (21.0 %) 2449 (94.2 %) 151 (5.8 %)
 United States 2465 2092 (84.9 %) 373 (15.1 %) 2345 (95.1 %) 120 (4.9 %)
 Asia 709 312 (44.0 %) 397 (56.0 %) 562 (79.3 %) 147 (20.7 %)
Race
 Asian 919 420 (45.7 %) 499 (54.3 %) 741 (80.6 %) 178 (19.4 %)
 Black 771 632 (82.0 %) 139 (18.0 %) 725 (94.0 %) 46 (6.0 %)
 Other 403 298 (73.9 %) 105 (26.1 %) 374 (92.8 %) 29 (7.2 %)
 Caucasian 7170 5980 (83.4 %) 1190 (16.6 %) 6838 (95.4 %) 332 (4.6 %)
Ethnicity
 Hispanic or latino 1127 840 (74.5 %) 287 (25.5 %) 1070 (94.9 %) 57 (5.1 %)
 Not hispanic or latino 8136 6490 (79.8 %) 1646 (20.2 %) 7608 (93.5 %) 528 (6.5 %)
eGFR category (mL/min/1.73 m2)
 Normal (≥90) 3415 2654 (77.7 %) 761 (22.3 %) 3183 (93.2 %) 232 (6.8 %)
 Mild (60–90) 3831 3068 (80.1 %) 763 (19.9 %) 3590 (93.7 %) 241 (6.3 %)
 Moderate (30–60) 1842 1475 (80.1 %) 367 (19.9 %) 1742 (94.6 %) 100 (5.4 %)
 Severe (<30) 173 132 (76.3 %) 41 (23.7 %) 161 (93.1 %) 12 (6.9 %)
Smoker
 Current smoker 1117 833 (74.6 %) 284 (25.4 %) 1023 (91.6 %) 94 (8.4 %)
 Never smoked 3852 3057 (79.4 %) 795 (20.6 %) 3611 (93.7 %) 241 (6.3 %)
 Previous smoker 4294 3440 (80.1 %) 854 (19.9 %) 4044 (94.2 %) 250 (5.8 %)
CVD stratum
 No prior CVD group 1736 1398 (80.5 %) 338 (19.5 %) 1636 (94.2 %) 100 (5.8 %)
 Prior CVD group 7527 5932 (78.8 %) 1595 (21.2 %) 7042 (93.6 %) 485 (6.4 %)
Diabetes duration (years) 12.7 ± 8.0 12.5 ± 8.0 13.5 ± 8.3 12.6 ± 8.0 13.9 ± 8.7
HbA1c (%) 8.7 ± 1.5 8.7 ± 1.5 8.7 ± 1.6 8.7 ± 1.5 8.7 ± 1.7
HbA1c (mmol/mol) (71.6 ± 16.4) (71.6 ± 16.4) (71.6 ± 17.5) (71.6 ± 16.4) (71.6 ± 18.6)
Blood lipids
 LDL-C (mmol/L) 2.3 ± 0.9 2.3 ± 0.9 2.3 ± 0.9 2.3 ± 0.9 2.2 ± 0.9
 HDL-C (mmol/L) 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.3 ± 0.4
 Triglycerides (mmol/L) 2.1 ± 1.6 2.1 ± 1.6 1.7 ± 1.5 2.1 ± 1.6 1.6 ± 1.6
Blood pressure
 Systolic blood pressure (mmHg) 138 ± 19 138 ± 19 136 ± 19 138 ± 19 135 ± 18
 Diastolic blood pressure (mmHg) 78 ± 11 78 ± 11 77 ± 10 78 ± 11 76 ± 10
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respectively) and IISHMS (92.8 and 93.6 %, respectively) 
was also similar.
Female gender was less prevalent in the prior CVD 
cohort than those without prior CVD (33.5 vs. 45.4  %, 
respectively). There was also a lower prevalence of 
patients aged 60–69 years with prior CVD than patients 
without (46.1 vs. 76.5 %, respectively), and a higher pro-
portion of patients aged 50–59  years with prior CVD 
than patients without (30.2 vs. 1.5 %, respectively). Fur-
thermore, there was also a lower prevalence of patients 
at target LDL-C with prior CVD than those without 
(33.2 vs. 56.6  %, respectively). Comparing patients with 
prior CVD with those without, there was a greater preva-
lence of patients not using oral antihyperglycaemic drugs 
(OADs) (48.3 vs. 42.6 %, respectively). Additionally, com-
paring patients with prior CVD with those without, there 
was a greater prevalence of patients using antihyperten-
sive medication (93.2 vs. 84.3 %, respectively).
Stratified by BMI and WC
Mean BMI was 32.5  ±  6.3  kg/m2 and only 9.1  % of 
patients had a BMI  <25  kg/m2. The prevalence of over-
weight, obesity grade I, obesity grade II, and obesity grade 
III was 28.6, 32.0, 18.4 and 11.7 %, respectively (Table 2). 
The mean WC was 109.9 ± 16.2 cm and the overall prev-
alence of abdominal obesity according to ATPIII and 
IISHMS was 79.1 and 93.6 %, respectively (Table 3).
BMI was higher in females than in males (BMI 
33.6  ±  6.8  kg/m2 vs. 31.9  ±  5.9  kg/m2, respectively; 
p  <  0.0001). WC was lower in females than males 
(107.6  ±  15.6  cm vs. 111.2  ±  16.3  cm, respectively; 
p  <  0.0001). Moreover, due to gender-specific cut-
offs, the prevalence of abdominal obesity was higher in 
females than males when measured independently from 
the WC criteria (ATPIII: 92.3 vs. 71.8 %; IISHMS 97.8 vs. 
91.4 %, respectively; p < 0.0001).
Younger patients were heavier with age (per year) 
being inversely correlated with BMI (p < 0.0001) and WC 
(p < 0.0001). Similar patterns were observed among BMI 
categories.
The prevalence of prior CVD was similar across all BMI 
categories (80.1, 80.5, 82.1, 81.9 and 80.8 %, respectively; 
p = 0.4491) and WC categories for both criteria (ATPIII: 
80.9 vs. 82.5 %; IISHMS: 81.1 vs. 82.9 %).
Twelve percent of patients were current smokers, and 
46 % were previous smokers. Tables 2 and 3 show that the 
prevalence of current smokers was higher, and the preva-
lence of previous smokers was lower in patients with nor-
mal BMI and WC when compared with higher BMI and 
WC categories.
A significant decrease in diabetes duration with 
increasing degrees of obesity was observed across BMI 
(p = 0.0001) and WC (p = 0.0044) categories.
Obesity and overweight were more frequent in 
Caucasian and Black individuals than in Asian or 
“other” races. Thus, the prevalence of patients with 
BMI  <25  kg/m2 among races was highest in Asian peo-
ple followed by “Other race”, Black and Caucasian people 
(35.4, 14.0, 6.9 and 5.9 %, respectively; p < 0.0001). Also, 
the percentage of subjects with healthy WC according to 
ATPIII and IISHMS was higher in Asian people follow-
ing the same order as BMI (ATPIII: 54.3, 26.1, 18.0 and 
16.6 %; IISHMS: 19.4, 7.2, 6.0 and 4.6 %; p < 0.0001).
Regarding demographic areas, the highest prevalence 
of overweight and obesity and central adiposity was in 
the USA, followed by Europe, “Other areas” and Asia 
(p  <  0.0001). Consequently, the prevalence of normal 
weight in the USA, Europe, “Other areas” and Asia was 
4.8, 5.9, 10.6 and 14.0 %, respectively.
Similar patterns of association between obesity (accord-
ing to BMI and WC categories), age, gender, prior CVD, 
tobacco use and diabetes duration were observed when 
different races and ethnicities were analysed separately.
Cardiometabolic risk factors and medication use
Cardiometabolic risk factors and medication use by BMI 
and WC categories are shown in Tables  2 and 3 and 
Figs. 1 and 2, respectively. A summary of the prevalence of 
patients for each BMI and WC class are provided in Fig. 3.
Unadjusted observed values for triglycerides (TG) 
were positively correlated with BMI (p < 0.0001) and WC 
(p < 0.0001). HDL-C was negatively correlated with BMI 
(p  <  0.0001) and WC (p  <  0.0001). Positive correlations 
were also found for BP with BMI and WC. No significant 
correlations were found between HbA1c and BMI or WC.
In the Chi squared analysis (unadjusted), the percent-
age of patients with target levels of TG, HDL-C and BP 
dropped significantly with increasing BMI (Fig.  1a). 
However in the case of HbA1c on target, this trend 
was reversed; the percentage of patients with HbA1c 
at target increased significantly with increasing BMI 
(BMI >25 kg/m2) (Fig. 1a). A similar trend was observed 
for both WC criteria (Fig. 1b).
Obese patients were more likely to be on insulin. The 
prevalence of patients on insulin was significantly lower 
in patients with normal weight (Fig.  2a) and normal 
abdominal waist circumference (Fig. 2b) compared with 
higher BMI and WC categories. There was a higher per-
centage of patients on OADs plus insulin at higher BMI 
(>25 kg/m2) and off-target WC categories (Fig. 2).
In the same way, obese patients were more likely to 
be treated with statins and antihypertensive medication 
than those of normal weight. The prevalence of patients 
on these drugs was greater at higher BMI (Fig.  2a) and 
WC (Fig.  2b) categories. Also, patients with higher 
BMI (>25  kg/m2) were taking a greater number of 
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Fig. 1 Percentage of patients with cardiometabolic parameters at target among (a) BMI and (b) WC categories. Statistics. p values of BMI or WC vs. 
factors were calculated using Chi square test.***p < 0.0001; **p < 0.001; *p < 0.01. ATPIII, adult treatment panel III criteria; BMI, body mass index;  
BP, blood pressure; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; IISHMS, International Joint Interim Statement for the 
Harmonization of the Metabolic Syndrome criteria; LDL-C, low-density lipoprotein cholesterol; OADs, oral antihyperglycaemic drugs; TG, triglycer-
ides; WC, waist circumference
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antihypertensive agents (p  <  0.0001). Despite the lipid-
modifying therapy and higher numbers of antihyperten-
sive drugs, the lipid profile and BP were worse in obese 
patients than in those of normal weight. On the contrary, 
no difference in glycaemic control (HbA1c) was found 
between BMI and WC categories.
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Fig. 2 Percentage of patients with relevant medication among (a) BMI and (b) WC categories. Statistics. p values of BMI or WC vs. factors were 
calculated using Chi square.***p < 0.0001; **p < 0.001; *p < 0.01. ATPIII, adult treatment panel III criteria; BMI, body mass index; IISHMS, International 
Joint Interim Statement for the Harmonization of the Metabolic Syndrome criteria; OADs, oral antihyperglycaemic drugs; WC, waist circumference
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Multivariable logistic regressions modelling BMI and WC
Multivariable binary logistic regression models using 
BMI ≥30  kg/m2 and off-target WC (using IISHMS and 
ATPIII) as dependent variables, and relevant demo-
graphic, clinical, cardiometabolic and medication param-
eters as independent variables, were performed in order 
to elucidate which variables were more related with being 
obese when having T2DM (Table 4). These analyses are 
adjusted data, providing the overall relationship of fac-
tors with obesity, and therefore supersede the unadjusted 
data.
As shown in Table  4, binary logistic regressions 
revealed that being obese (BMI ≥30 kg/m2) was signifi-
cantly associated with being younger, female, previous 
smoker (vs. current smoker), Caucasian (vs. Asian, Black 
or other races), not Hispanic or Latino (vs. not Hispanic 
or Latino), from the USA (vs. Asia, Europe, or other 
areas), shorter diabetes duration, having uncontrolled BP, 
reduced estimated glomerular filtration rate (eGFR), anti-
hypertensive drug intake (four antihypertensive drugs 
vs. zero, one or two antihypertensive drugs), insulin plus 
OAD treatment (vs. OADs only), high levels of TG and 
lower levels of LDL-C and HDL-C.
Regarding WC, abdominal obesity according to 
ATPIII was significantly and positively related to the 
same variables as BMI  ≥30 kg/m2, with the exception 
of age, reduced eGFR and no pre-treatment/diet only. 
In contrast, when the IISHMS were applied, abdominal 
obesity was mainly related to being female (vs. male), 
previous smoker (vs. current smokers), Caucasian (vs. 
Asian), from the USA (vs. Asia or other areas), antihy-
pertensive drug intake (four antihypertensive drugs vs. 
zero antihypertensive drugs), insulin plus OAD treat-
ment (vs. OADs only), higher levels of TG and lower 
levels of HDL-C. The associations for hypertension and 
antihypertensive drug intake were less significant when 
considering IISHMS compared to ATPIII indicating 
that, at least for BP, the larger the abdominal circumfer-
ence, the larger the cardiometabolic impact. There was 
no statistically significant relationship between HbA1c 
and the obesity criteria evaluated. Likewise, despite the 
relationship between eGFR and BMI, no correlation was 
determined between the albumin–creatinine ratio and 
BMI or WC criteria.
Discussion
Our principal finding is that in this very high-risk popula-
tion of patients with T2DM, the prevalence of overweight 
(28.6 %) and obesity (61.7 %) is very high. Only 9.1 % of 
the patients were of normal weight. Likewise, only 20.9 
and 6.3 % of patients had a healthy WC according to the 
ATPIII and IISHMS for metabolic syndrome, respec-
tively. The baseline data from the LEADER trial gave us 
the opportunity to study the prevalence of overweight 
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Table 4 An overview of  multivariable logistic regression: baseline characteristics associated with  obesity 
(BMI ≥ 30 kg/m2) and increased waist circumference (WC-ATPIII and WC-IISHMS) off target
The full list of variables used were age, sex, smoking status, region, race, ethnicity, CVD stratum, diabetes duration, HbA1c, hypertension, number of antihypertensive 
drugs, eGFR, LDL-C, HDL-C, triglycerides, albumin/creatinine ratio, statin use, hyperlipidaemia, aspirin use and number of previous antihypertensive agents. ATPIII 
Adult treatment panel III criteria; BMI body mass index; eGFR estimated glomerular filtration rate; HbA1c glycated haemoglobin; HDL-C high-density lipoprotein 
cholesterol; IISHMS International Joint Interim Statement for the Harmonization of the Metabolic Syndrome criteria; LDL-C low-density lipoprotein cholesterol; OADs 
oral antihyperglycaemic drugs; SD standard deviation; WC waist circumference
BMI ≥30 kg/m2 WC-ATPIII off target WC-IISHMS off target
Odds ratio 95 % CI for OR p value Odds ratio (95 % CI for OR) p value Odds ratio (95 % C.I. for OR) p value
Age (per year) 0.956 (0.949–0.964) <0.0001 0.998 (0.988–1.007) 0.6461 1.005 (0.990–1.021) 0.5158
Gender
 Male 0.597 (0.525–0.678) <0.0001 0.136 (0.112–0.164) <0.0001 0.190 (0.137–0.259) <0.0001
 Female 1.000 (1.000–1.000) – 1.000 (1.000–1.000) – 1.000 (1.000–1.000) –
Smoking status
 Current smoker 0.612 (0.517–0.724) <0.0001 0.627 (0.516–0.764) <0.0001 0.604 (0.453–0.813) 0.0007
 Never smoked 0.927 (0.821–1.046) 0.2189 0.797 (0.689–0.922) 0.0022 0.911 (0.724–1.148) 0.4295
 Previous smoker 1.000 (1.000–1.000) – 1.000 (1.000–1.000) – 1.000 (1.000–1.000) –
Region
 Asia 0.207 (0.137–0.314) <0.0001 0.361 (0.240–0.543) <0.0001 0.358 (0.199–0.625) 0.0004
 Europe 0.500 (0.430–0.579) <0.0001 0.685 (0.569–0.823) 0.0001 0.901 (0.659–1.227) 0.5106
 Other areas 0.495 (0.426–0.576) <0.0001 0.646 (0.536–0.777) <0.0001 0.683 (0.504–0.925) 0.0140
 United States 1.000 (1.000–1.000) – 1.000 (1.000–1.000) – 1.000 (1.000–1.000) –
Race
 Asian 0.226 (0.159–0.317) <0.0001 0.240 (0.168–0.341) <0.0001 0.473 (0.290–0.803) 0.0039
 Black 0.663 (0.545–0.808) <0.0001 0.628 (0.493–0.804) 0.0002 0.690 (0.474–1.020) 0.0565
 Other 0.598 (0.465–0.771) 0.0001 0.699 (0.521–0.944) 0.0180 0.782 (0.482–1.324) 0.3368
 Caucasian 1.000 (1.000–1.000) – 1.000 (1.000–1.000) – 1.000 (1.000–1.000) –
Ethnicity
 Hispanic or latino 0.528 (0.446–0.625) <0.0001 0.545 (0.445–0.668) <0.0001 1.121 (0.790–1.620) 0.5311
 Not hispanic or latino 1.000 (1.000–1.000) – 1.000 (1.000–1.000) – 1.000 (1.000–1.000) –
HbA1c (mmol/mol) 0.999 (0.995–1.002) 0.4850 0.999 (0.995–1.003) 0.7628 0.995 (0.989–1.002) 0.1402
Diabetes duration per year 0.983 (0.977–0.990) <0.0001 0.981 (0.973–0.989) <0.0001 0.982 (0.970–0.995) 0.0051
Hypertension (>140/80 mm Hg)
 No 0.779 (0.696–0.871) <0.0001 0.862 (0.754–0.984) 0.0281 0.862 (0.701–1.062) 0.1623
 Yes 1.000 (1.000–1.000) – 1.000 (1.000–1.000) – 1.000 (1.000–1.000) –
Blood lipids
 LDL-C (mmol/L) 0.903 (0.848–0.963) 0.0018 0.914 (0.845–0.988) 0.0234 1.029 (0.907–1.170) 0.6590
 HDL-C (mmol/L) 0.620 (0.511–0.752) <0.0001 0.516 (0.411–0.646) <0.0001 0.416 (0.303–0.574) <0.0001
 Triglycerides (mmol/L) 1.278 (1.192–1.370) <0.0001 1.417 (1.298–1.548) <0.0001 1.680 (1.438–1.974) <0.0001
eGFR (mL/min/1.73 m2) 0.998 (0.996–1.000) 0.0209 1.001 (0.998–1.003) 0.6185 1.001 (0.997–1.005) 0.5649
Albumin-creatinine ratio 
(per doubling)
0.994 (0.971–1.017) 0.5823 1.016 (0.989–1.044) 0.2459 1.012 (0.970–1.055) 0.5866
Number of antihypertensive drugs
 0 0.306 (0.217–0.428) <0.0001 0.320 (0.207–0.483) <0.0001 0.364 (0.175–0.693) 0.0037
 1 0.558 (0.411–0.751) 0.0002 0.543 (0.364–0.790) 0.0020 0.757 (0.374–1.390) 0.4013
 2 0.599 (0.443–0.801) 0.0007 0.615 (0.415–0.890) 0.0125 0.686 (0.343–1.244) 0.2484
 3 0.862 (0.627–1.175) 0.3546 0.860 (0.567–1.277) 0.4659 1.217 (0.580–2.361) 0.5793
 4 1.000 (1.000–1.000) – 1.000 (1.000–1.000) – 1.000 (1.000–1.000) –
Pretreatment
 Insulin + OADs 1.298 (1.153–1.463) <0.0001 1.281 (1.110–1.480) 0.0007 1.525 (1.213–1.926) 0.0003
 Insulins use 1.022 (0.826–1.266) 0.8418 1.040 (0.808–1.345) 0.7625 1.196 (0.804–1.830) 0.3931
 None/diet 1.297 (1.018–1.660) 0.0372 1.174 (0.881–1.582) 0.2821 1.208 (0.779–1.949) 0.4189
 OADs use 1.000 (1.000–1.000) – 1.000 (1.000–1.000) – 1.000 (1.000–1.000) –
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and obesity in a high CV risk population with T2DM, 
and also the association with a set of cardiometabolic risk 
factors and their treatment intensity.
Worldwide, the proportion of adults with BMI ≥25 kg/m2 
is estimated to be 36.9 % in men and 38.0 % in women. 
These figures range from 20.2–22.5  % in South Asia to 
70.3 and 60.5 % in high-income North America [17]. In 
the USA, data from the National Health and Nutrition 
Examination Survey (NHANES) 2005–2010 indicate a 
prevalence of patients with T2DM with a BMI ≥25 kg/m2 
to be 87.1 % (BMI >30 kg/m2: 61.2 %) [18]. In high-risk 
patients with T2DM, data from the Bypass angioplasty 
revascularization investigation in type 2 diabetes (BARI-
2D) trial in patients with T2DM and documented coro-
nary artery disease showed the prevalence of obesity 
(BMI  ≥30  kg/m2) to be 56.4  % [19]. Similarly, in the 
saxagliptin assessment of vascular outcomes recorded in 
patients with diabetes mellitus (SAVOR)–thrombolysis 
in myocardial infarction (TIMI) 53 study, the prevalence 
of obesity (BMI ≥30 kg/m2) was 53 % [20].
An unexpected and novel finding was an inverse cor-
relation between diabetes duration and both BMI and 
WC. Recently, an inverse correlation between BMI 
strata, diabetes duration and age has also been reported 
in a pooled analysis of cross-sectional data from Spanish 
patients with a mean age of 63.2 years [21]. This inverse 
relationship could suggest less advanced disease and/or 
the absence of comorbidities in patients with a higher 
BMI, which could be related to a higher survival prob-
ability in overweight patients with T2DM or previous 
CV disease in prospective studies [22]. The negative 
association between disease duration and baseline BMI 
could, therefore, be due to survivor bias: the patients 
with persistently high BMI would have a greater likeli-
hood of dying before study enrolment than those with 
lower BMI.
In our study, obesity was more prevalent in younger 
patients, women, Caucasians, “non-Hispanic or Latinos”, 
and previous smokers when compared with correspond-
ing groups. These observations seem to be consistent 
with data from the BARI-2D, a trial that featured a com-
parable population regarding age and BMI [19].
The higher BMI and lower WC observed in females 
compared with men are in line with previous findings 
that men have greater levels of visceral fat compared 
with women; thus, T2DM and CV disease may develop 
at a lower BMI level in men than in women [23, 24]. Also, 
the higher percentage of individuals of normal weight 
and with a healthy WC among Asian and Hispanic high-
risk patients, even according to IISHMS, indicates that 
these individuals would have developed T2DM and have 
a higher CV risk at lower BMI and WC. Accordingly, 
the recent cross-sectional study from the UK Biobank 
Participants (which included 490,288 subjects) con-
cludes that obesity should be defined by a lower thresh-
old in non-Caucasian than in Caucasian populations [10]. 
For instance, for T2DM diagnosis, a BMI of 30 kg/m2 in 
Caucasians equates to 22 kg/m2 in South Asians, and for 
respective WCs, 102 cm equates to 79 cm [10].
Obesity and cardiometabolic risk factors
In common with other studies, we did not find an asso-
ciation between weight and HbA1c level through our 
logistic analysis [19, 21, 25]. Conversely, we did observe 
an association between BMI and WC and several cardio-
metabolic risk factors, despite the more frequent use of 
statins and antihypertensives in higher BMI and WC cat-
egories. Primarily, obesity was associated with higher BP 
levels, higher levels of TG and low levels of HDL-C. This 
association was observed both across the trial population 
and after adjustment for potential confounding factors 
that are also related to obesity. These results are generally 
consistent with data from observational studies both in 
the general population and in high CV risk patients with 
T2DM [3, 20, 21, 25–28]. Also, a significant association 
of reduced eGFR with BMI (but not WC) was observed, 
consistent with kidney dysfunction data from the 
BARI-2D trial [19].
Obesity and treatment intensity
When we analysed the influence on lipid levels, the 
numbers of patients treated with lipid-modifying agents 
increased with increasing categories of BMI and WC. 
However, obese patients were less likely to be at the 
defined lipid targets, especially for HDL-C and TG levels. 
While the association between statin treatment and BMI 
is quite consistent in the medical literature [19, 26, 29–
31], a greater discrepancy exists around the probability of 
LDL-C reaching target levels [26, 30].
The percentage of patients not receiving statins at 
baseline was 24.7  %. Similarly, the baseline prevalence 
of patients not treated with statins has been reported 
to be 20  % in the TECOS trial (TECOS; trial evaluat-
ing CV outcomes with sitagliptin) [32]. It is also a con-
cern that a high percentage of patients with T2DM with 
normal adiposity measurements are not treated with 
statins, despite clinical practice guidelines recommend-
ing that high-risk patients with T2DM should be treated 
with a statin regardless of lipid levels [33, 34]. The latter 
is based on data showing that statins may have cardio-
protective effects extending beyond their cholesterol-
lowering properties [35]. Similarly, patients with normal 
weight were less likely to be treated with antihypertensive 
agents compared to overweight patients, even though, 
similar to statins, some antihypertensive agents have 
shown vascular protective properties [36]. This treatment 
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disequilibrium between lean and obese patients could 
contribute to the so-called “obesity paradox” [3].
Finally, analyses of other large randomised trials indi-
cate that a significant proportion of patients with T2DM 
and coronary artery disease fail to achieve pre-specified 
targets for the major modifiable CV risk factors, sug-
gesting that a combination of barriers may be prevent-
ing goals attainment [37]. Our results show that this 
gap is larger in obese patients with T2DM despite more 
intensive treatment. It is worth remembering, however, 
that we present data available at the time after end of 
the recruitment. The Standard of Care Guidelines for 
LEADER, developed by the Global Expert Panel, recom-
mended statins for all patients and the following targets: 
HbA1c <7.0 % (53.0 mmol/mol) (individualised depend-
ing on the patient), LDL-C <2.6 mmol/l (<1.8 mmol/l in 
patients with previous CV disease) and BP 130/80 mmHg 
[7]. Therefore, a cardiometabolic improvement for all 
participants regardless of treatment allocation could be 
observed during the trial.
Strengths and limitations
Strengths of our study include the large number of 
patients studied from a multinational and multi-ethnic 
population, and the context of a clinical trial where a 
central laboratory was used. The investigators collected 
data according to a standard protocol. Furthermore, tak-
ing into account not only BMI but also WC as a more 
accurate measure of visceral adiposity is a strength com-
pared with previous studies. Finally, our sample allowed 
us to study two high-risk groups of patients: a cohort 
with prior CVD and a high-risk cohort but without prior 
CVD. Also, the multiracial population potentially makes 
our data more generalisable.
In interpreting our findings, however, several impor-
tant limitations need to be considered. The context of a 
clinical trial may generate a selection bias and diminish 
the generalisability of the results. Thus, given the known 
effect of liraglutide to promote weight loss [38], over-
weight and obesity may be over-represented in LEADER. 
Also, the observation that only patients  >50  years were 
enrolled in LEADER is important because some studies 
suggest that the relationship between BMI and CV risk 
could be modified by age; thus, the findings may not be 
generalisable to a younger population. In particular, a 
prospective analysis of individual records of 221,934 peo-
ple indicated that the increased risk of CVD (myocardial 
infarction and ischaemic stroke) associated with BMI 
and WC was 3–4 times higher at the age of 40–59 years 
than at 70 years [39]. Nevertheless, post hoc analyses of 
the SCOUT trial that recruited patients ≥55 years con-
firmed a relationship between weight loss and CV risk 
factors (such as total cholesterol) and outcomes (such as 
CV mortality) [40, 41]. Furthermore, although including 
patients <50 years, studies have shown an association of 
obesity with suboptimal control of CV risk factors in dia-
betic patients across the mean age range of 62–65.7 years 
[2, 19, 21, 28].
Another limitation to these findings is the two distinct 
cohorts used in this study. Female gender, for exam-
ple, showed lower prevalence in the patients with prior 
CVD cohort than in those without prior CVD (33.5 vs. 
45.4 %, respectively); there were also large differences in 
prevalence between patients with prior CVD and those 
without in patients aged 50–59  years (30.2 vs. 1.5  %, 
respectively), aged 60–69 years (46.1 vs. 76.5 %, respec-
tively) and those using hypertensive medication (6.8 vs. 
15.7 %, respectively).
A further limitation is the cross-sectional nature of the 
study that precludes determination of causality. Further-
more, although our analyses are adjusted for multiple 
variables, these might have different effects in longitudi-
nal studies. In addition, the use of single baseline values 
for blood pressure, cholesterol, and markers of glycaemia 
has been criticised because of their potential for error in 
measurement and within-patient fluctuation [42].
Unfortunately, detailed information about the drug 
classes, doses and treatment adherence were not available 
at the time this manuscript was developed, and therefore, 
the authors could not accurately evaluate the association 
between adiposity and treatment intensity. Finally, we did 
not have data on risk-taking behaviours such as unhealthy 
diet, sedentary lifestyle, and alcohol intake, among others, 
that could confound the relationship between adiposity 
and attainment of treatment target.
When entering the treatment phase, an important 
aspect is the demonstrated beneficial effects of GLP-1RA 
on weight. Exenatide once weekly has been, at least 
partly, associated with weight loss and reduced macro-
vascular risk in a retrospective study and a pooled analy-
ses of eight studies [43, 44]. A retrospective longitudinal 
pharmaco-epidemiological study established that the risk 
for composite of myocardial infarction or stroke in over-
weight and obese patients were not significantly higher 
compared to those in the normal weight group after 
adjusting for other factors [43]. Also, the rates/1000 per-
son years of individual CV events in the same study were 
not significantly different by BMI categories (normal 
weight, overweight and obese) regardless of treatment 
groups in the study cohort [43]. Moreover, a pooled anal-
ysis from eight studies of exenatide once weekly showed 
that the greatest trend of improvement in CV risk factors 
was observed in patient quartiles with the greatest reduc-
tions in body weight [44]. Following the same relation-
ship as exenatide, liraglutide has demonstrated beneficial 
changes in weight and body composition; indeed, 12 and 
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56 week trials specifically designed to study the efficacy 
and safety of liraglutide for weight management have 
shown reductions in body weight and enhanced meta-
bolic parameters (such as B-type ventricular natriuretic 
peptide, fasting lipids and urinary albumin-to-creatinine 
ratio) [45–47].
In summary, overweight and obesity are extremely prev-
alent in high-risk patients with T2DM. Furthermore, BMI 
and WC are related to major cardiometabolic risk fac-
tors, particularly BP, TG, and HDL-C. In addition, treat-
ment intensity is higher in overweight and obese patients, 
compared with others; however, the rates of treatment 
and control of lipids and BP are remarkably suboptimal 
in overweight and obese individuals. As secondary data, 
LEADER will explore the longitudinal effects of liraglutide 
or placebo, when added to standard care, on CV risk fac-
tors and weight for up to 5 years of treatment.
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